Thrombosis Clinical Trial Landscape
Data updated: May 20, 2026
273 clinical trials tracked since 2008
Thrombosis is being studied across 273 clinical trials registered since 2008, with 49 programs currently active. The competitive pipeline includes 26 active Phase 3 trials, 7 active Phase 2 trials, and 1 active Phase 1 trials. Top industry sponsors include Regeneron, Boston Scientific Corporation, Supergene, LLC.
49 active
/
273 total (since 2008)
1
Phase 1 Active
25 total
7
Phase 2 Active
59 total
26
Phase 3 Active
119 total
17
Phase 4 Active
81 total
Top Industry Sponsors
Sorted by active Active Done Failed
Regeneron 3 3 0
Boston Scientific Corporation 1 4 1
Supergene, LLC 1 1 0
Quercis Pharma AG 1 0 0
Sirius Therapeutics Co., Ltd. 1 0 0
+ 8 more sponsors — see full table below
Featured Phase 3 Trials
NCT07015905 RECRUITING
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Regeneron Pharmaceuticals n=2,000
NCT07213778 RECRUITING
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Regeneron Pharmaceuticals n=2,000
NCT05591118 RECRUITING
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NYU Langone Health n=500
NCT07140211 RECRUITING
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Marc Blondon n=9,200
NCT07005024 RECRUITING
DOAC - Dosing Options in AntiCoagulation Prophylaxis
University of Vermont n=996
+ 114 more Phase 3 trials — see full database below
Thrombosis — Trials Started by Year (last 10 years)
2016 18
2017 23
2018 11
2019 13
2020 15
2021 14
2022 8
2023 8
2024 18
2025 15
2026 6
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Regeneron 6
Boston Scientific Corporation 6
Supergene, LLC 2
Quercis Pharma AG 1
Sirius Therapeutics Co., Ltd. 1
Bayer 9
Boehringer Ingelheim 8
Daiichi Sankyo 7
Sanofi 7
Astellas Pharma Inc 6
Active Trials by Phase
Phase 1 1
Phase 2 7
Phase 3 26
Phase 4 17
Enrollment Size Distribution
1-50 66
51-200 78
201-500 51
501-1k 22
1k+ 42
All Industry Sponsors
Sorted by active Active Done Failed
Regeneron 3 3 0
Boston Scientific Corporation 1 4 1
Supergene, LLC 1 1 0
Quercis Pharma AG 1 0 0
Sirius Therapeutics Co., Ltd. 1 0 0
Bayer 0 9 0
Boehringer Ingelheim 0 7 1
Daiichi Sankyo 0 6 1
Sanofi 0 6 1
Astellas Pharma Inc 0 6 0
Daiichi Sankyo Co., Ltd. 0 5 0
Bristol-Myers Squibb 0 2 1
Crux Biomedical 0 3 0
NCT07015905 RECRUITING
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Regeneron Pharmaceuticals n=2,000
NCT07213778 RECRUITING
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Regeneron Pharmaceuticals n=2,000
NCT05591118 RECRUITING
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NYU Langone Health n=500
NCT06628778 NOT YET RECRUITING
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
Johns Hopkins All Children's Hospital n=802
NCT06453876 NOT YET RECRUITING
Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II)
Jesper Kjaergaard n=210
NCT07493304 NOT YET RECRUITING
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Regeneron Pharmaceuticals n=1,600
NCT07432529 NOT YET RECRUITING
Design and Rationale of the COLT Study
Azienda Sanitaria Locale ASL 6, Livorno n=940
NCT07140211 RECRUITING
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Marc Blondon n=9,200
NCT07005024 RECRUITING
DOAC - Dosing Options in AntiCoagulation Prophylaxis
University of Vermont n=996
NCT06861088 RECRUITING
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Quercis Pharma AG n=480
NCT06393868 RECRUITING
Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism
Ottawa Hospital Research Institute n=360
NCT04319627 RECRUITING
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Ottawa Hospital Research Institute n=2,700
NCT06440694 RECRUITING
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
Ottawa Hospital Research Institute n=150
NCT06195540 RECRUITING
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
University Hospital, Angers n=1,424
NCT06362746 RECRUITING
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Supergene, LLC n=486
NCT07228663 NOT YET RECRUITING
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
McMaster University n=100
NCT06580223 NOT YET RECRUITING
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=530
NCT05920343 RECRUITING
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Ottawa Hospital Research Institute n=120
NCT05029063 RECRUITING
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Ottawa Hospital Research Institute n=1,828
NCT04430569 RECRUITING
Pulmonary Embolism International THrOmbolysis Study-3
Assistance Publique - Hôpitaux de Paris n=800
NCT06494878 NOT YET RECRUITING
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
University of Calgary n=8,805
NCT06611319 RECRUITING
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Prof. Stavros Konstantinides, MD n=2,932
NCT04088292 ACTIVE NOT RECRUITING
Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism
Rigshospitalet, Denmark n=210
NCT06662253 NOT YET RECRUITING
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
Alexandre Tran n=150
NCT04257487 RECRUITING
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Arianna Anticoagulazione Foundation n=1,455
NCT04981327 NOT YET RECRUITING
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
University Hospital, Geneva n=1,300
NCT05171075 TERMINATED
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Anthos Therapeutics, Inc. n=417
NCT05171049 TERMINATED
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Anthos Therapeutics, Inc. n=1,150
NCT03634124 COMPLETED
Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs
Centre Hospitalier Universitaire de Nīmes n=146
NCT07124819 COMPLETED
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
Avexima Diol LLC n=215
NCT02066454 COMPLETED
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
University Hospital, Grenoble n=108
NCT03045406 COMPLETED
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Fadoi Foundation, Italy n=1,170
NCT03080883 COMPLETED
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United n=370
NCT04688320 COMPLETED
Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
Supergene, LLC n=310
NCT05033314 TERMINATED
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
University Health Network, Toronto n=4
NCT02798471 COMPLETED
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
Daiichi Sankyo n=290
NCT01130025 COMPLETED
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
LEO Pharma n=900
NCT03506815 COMPLETED
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Ottawa Hospital Research Institute n=105
NCT05104229 WITHDRAWN
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Stefan Holubar MD MS FACS, FASCRS
NCT04670432 COMPLETED
Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis
Maastricht University Medical Center n=44
NCT02604238 WITHDRAWN
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
Azienda U.S.L. 1 di Massa e Carrara
NCT03285438 COMPLETED
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
University Hospital, Brest n=2,774
NCT02829957 COMPLETED
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
Indiana University n=19
NCT01583218 COMPLETED
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Portola Pharmaceuticals n=7,513
NCT05878899 COMPLETED
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
University Hospital, Geneva n=77
NCT04248868 COMPLETED
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Thrombolex, Inc. n=109
NCT03090880 TERMINATED
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
Assistance Publique - Hôpitaux de Paris n=59
NCT00680628 TERMINATED
Clot Dissolving Treatment for Blood Clots in the Lungs
Wake Forest University Health Sciences n=83
NCT05515120 COMPLETED
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Instituto Mexicano del Seguro Social n=58
NCT04003116 COMPLETED
Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)
Ministry of Health, Spain n=70
NCT02555111 COMPLETED
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Assistance Publique - Hôpitaux de Paris n=112
NCT02379806 COMPLETED
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
University Hospital, Brest n=2,560
NCT04400799 TERMINATED
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
University of Zurich n=475
NCT04662684 COMPLETED
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
Science Valley Research Institute n=320
NCT03055026 COMPLETED
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
Fadoi Foundation, Italy n=582
NCT05185804 COMPLETED
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
PharmaDiall Ltd. n=399
NCT02774265 COMPLETED
A Different Approach to Preventing Thrombosis
University of Maryland, Baltimore n=329
NCT05172115 TERMINATED
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
Rajaie Cardiovascular Medical and Research Center n=94
NCT01573169 TERMINATED
PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients
University Of Perugia n=73
NCT01166997 COMPLETED
ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Boston Scientific Corporation n=59
NCT01513759 COMPLETED
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Boston Scientific Corporation n=150
NCT02583191 TERMINATED
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH n=246
NCT03966079 COMPLETED
Thrombolysis Endovascular Treatment of Pulmonary Embolism
Beijing Tsinghua Chang Gung Hospital n=50
NCT02585713 COMPLETED
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United n=300
NCT01895777 COMPLETED
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
Boehringer Ingelheim n=267
NCT02197416 COMPLETED
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
Boehringer Ingelheim n=214
NCT02234843 COMPLETED
EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
Bayer n=500
NCT02935530 COMPLETED
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Huazhong University of Science and Technology n=315
NCT01181102 COMPLETED
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Daiichi Sankyo Co., Ltd. n=716
NCT01857583 COMPLETED
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
Daiichi Sankyo Co., Ltd. n=80
NCT01181141 COMPLETED
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
Daiichi Sankyo Co., Ltd. n=92
NCT01181167 COMPLETED
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Daiichi Sankyo Co., Ltd. n=610
NCT00986154 COMPLETED
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Daiichi Sankyo n=8,292
NCT02746185 COMPLETED
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
Assistance Publique - Hôpitaux de Paris n=159
NCT02767232 WITHDRAWN
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
University of Colorado, Denver
NCT01431456 COMPLETED
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Martini Hospital Groningen n=148
NCT00790335 COMPLETED
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Washington University School of Medicine n=692
NCT01720108 COMPLETED
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty
David Anderson n=3,426
NCT02064439 COMPLETED
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Bayer n=3,365
NCT02920125 COMPLETED
Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.
Sujata Vaidya n=96
NCT01274637 COMPLETED
PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
Ottawa Hospital Research Institute n=62
NCT01308528 COMPLETED
Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery
Cristália Produtos Químicos Farmacêuticos Ltda. n=243
NCT01516814 COMPLETED
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
Bayer n=40
NCT01516840 COMPLETED
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
Bayer n=60
NCT02368314 COMPLETED
A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
Biocad n=124
NCT01976988 COMPLETED
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
Cedars-Sinai Medical Center n=410
NCT01285661 COMPLETED
Optimal Duration of Anticoagulation in Deep Venous Thrombosis
University of Padova n=584
NCT01780987 COMPLETED
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
Pfizer n=80
NCT01880216 COMPLETED
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Berlin-Chemie AG Menarini Group n=312
NCT00876915 TERMINATED
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
University of Rochester n=218
NCT01458639 TERMINATED
Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism
Cyclomedica Australia PTY Limited n=18
NCT00902928 COMPLETED
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
Astellas Pharma Europe B.V. n=1,992
NCT01164046 TERMINATED
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
University Medical Center Groningen n=56
NCT00657150 COMPLETED
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
Boehringer Ingelheim n=2,055
NCT01120522 COMPLETED
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3")
Crux Biomedical n=17
NCT01120535 COMPLETED
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4
Crux Biomedical n=20
NCT01654042 WITHDRAWN
Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II
McMaster University
NCT00679588 COMPLETED
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
Sanofi n=4,413
NCT00709904 COMPLETED
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
Sanofi n=469
NCT00912483 WITHDRAWN
Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients
Azidus Brasil
NCT00721760 COMPLETED
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
Sanofi n=1,003
NCT00694382 COMPLETED
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Sanofi n=3,212
NCT00714597 TERMINATED
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
Sanofi n=421
NCT00697099 COMPLETED
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
Sanofi n=2,326
NCT00718224 COMPLETED
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
Sanofi n=1,150
NCT01234064 COMPLETED
Graduated Compression Stockings (GCS) Pilot Substudy
Hamilton Health Sciences Corporation n=50
NCT00937820 COMPLETED
Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
Astellas Pharma Inc n=87
NCT01164540 WITHDRAWN
Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
AstraZeneca n=3,000
NCT00917254 COMPLETED
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
Astellas Pharma Inc n=369
NCT00937911 COMPLETED
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
Astellas Pharma Inc n=101
NCT00942435 COMPLETED
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
Astellas Pharma Inc n=156
NCT01028950 COMPLETED
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
Astellas Pharma Inc n=52
NCT00913120 COMPLETED
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
Astellas Pharma Inc n=610
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only